COVID-19: Bacterial Co-Infections
Rapid Detection with Unyvero LRT/BAL

Learn More

Curetis Receives U.S. FDA 510(k) Clearance of Unyvero LRT for BAL Specimens.
The first and only FDA-cleared panel that detects Pneumocystis jirovecii in addition to a broad spectrum of clinically relevant bacterial pathogens and antibiotic resistance markers associated with pneumonia.

Read Press Release

The FDA-cleared Unyvero Lower Respiratory Tract infection panels help you quickly optimize antibiotic therapy.

Curetis magnifying glass icon

Detect the largest number of relevant pathogens and resistance markers*

Curetis stopwatch icon

Deliver rapid, reliable, and actionable answers

Curetis checklist icon

Enable earlier diagnosis and selection of optimal treatment

Unyvero LRT panels uniquely detect the most clinically relevant pathogens and resistance markers, including the broadest carbapenemase resistance coverage.*

For clear, comprehensive, and reliable results to advance antimicrobial stewardship initiatives, Unyvero points the way.

* Compared to other molecular panels.

The Unyvero Solution


Pathogen identification and resistance reported in just a matter of hours, using multiplex PCR technology


Excellent sensitivity and specificity with no growth required for detection of organisms and resistance genes, and results are not impacted by prior antibiotic use


Rapid detection of clinically relevant targets enables earlier optimal antibiotic decision


Enables testing during all microbiology laboratory shifts with an automated sample-to-answer process that drives results directly from specimen

What can Unyvero mean to you?

Microbiology Laboratories

Need to identify the pathogen and resistance quickly.

Infectious Disease

Need to know the cause to implement the right treatment plan.

Antibiotic Stewardship

Need to prescribe appropriate antibiotics for effective treatment.

Hospital Administration

Need to control healthcare costs, increase DRG yield and improve ROI.

Want to know more?